• Indomethacin: Identity and Evidence Boundaries

  2026-10-13

  The supplied APExBIO page identifies Indomethacin as a nonsteroidal anti-inflammatory drug and describes several proposed research contexts, including cyclooxygenase inhibition, PPAR-related signaling, lipid metabolism study, and membrane signaling modulation. Because no matched paper is available, these descriptions should be treated as product-level claims rather than evidence of outcomes, mechanism, selectivity, or practical utility in a specific model.

• Baicalein Research Context and Evidence Limits

  2026-10-13

  Baicalein, also known as 5,6,7-trihydroxy-2-phenylchromen-4-one, is described by APExBIO as a flavonoid research compound relevant to arachidonic acid metabolism, apoptosis, cancer cell proliferation inhibition, and inflammation pathway modulation. The supplied neurotoxicity study concerns formononetin rather than baicalein and provides mechanistic context—not direct evidence for baicalein’s effects or translational value.

• GPR35–KLF5 and the Logic of Epithelial Repair

  2026-10-12

  A source-grounded overview of a 2026 study proposing that GPR35 interprets tryptophan-metabolite signals and engages KLF5-dependent epithelial repair programs in ulcerative colitis. The evidence is mechanistically suggestive, but the supplied record does not provide numerical effect sizes or enough methodological detail to establish clinical relevance.

• Isochlorogenic Acid A: Evidence Boundaries

  2026-10-11

  A source-grounded overview of Isochlorogenic acid A and a reported preclinical hydrogel formulation, separating material characterization and wound-healing findings from claims that remain unproven.

• CD28–ARS2–PKM2 Drives CD8+ T-Cell Flexibility

  2026-10-10

  Holling and colleagues identify a CD28–ARS2 signaling axis that reshapes PKM alternative splicing and supports metabolic flexibility in activated CD8+ T cells. The findings connect costimulation to PKM2 expression, glucose utilization, interferon-γ production, and antitumor effector function independently of canonical CD28–PI3K signaling.

• MRSA Vesicles Drive Oral Cancer via IL-8

  2026-10-09

  A 2026 study links extracellular vesicles from methicillin-resistant Staphylococcus aureus to oral squamous cell carcinoma growth through an IL-8-centered signaling circuit. Its receptor-level evidence highlights CXCR1 as a key mediator while defining why CXCR2-focused chemotaxis research should not be treated as equivalent to tumor-cell signaling.

• Tetrandrine: Research Context and Evidence Limits

  2026-10-09

  Tetrandrine is a natural-product research compound associated with calcium-channel and signaling studies. This overview separates catalog information from peer-reviewed evidence, examines conceptual applications in ion channel modulation, neuroscience, inflammation, and cancer biology, and explains why a 2021 computational SARS-CoV-2 NSP15 study does not establish tetrandrine as an antiviral lead.

• EGCG Research Context, Findings, and Limitations

  2026-10-08

  (-)-Epigallocatechin gallate (EGCG) is a green tea catechin studied in infection, cancer, antiviral, and cell-signaling research. This overview examines the 2024 in vitro evidence for EGCG analogs against Staphylococcus aureus, compares it with broader product-level claims, and defines the main translational limitations.

• Obeticholic Acid in FXR and Liver Fibrosis Research

  2026-10-08

  Obeticholic Acid is a selective FXR agonist used to investigate bile acid regulation, cholestasis, inflammation, and fibrosis. This overview separates supplier-reported pharmacology from published evidence and compares FXR-centered research with findings from a 2025 study of 11β-HSD1 inhibition in mouse liver fibrosis.

• Procainamide Hydrochloride: Research Context

  2026-10-07

  Procainamide Hydrochloride is best understood as a compound with established cardiac electrophysiology relevance and additional, less mature research claims involving epigenetic and immunomodulatory biology. The supplied pregnancy-mouse study provides focused evidence about its use alongside cisplatin, but its findings do not establish clinical safety, general chemoprotection, or efficacy in humans.

• Sumatriptan Succinate: From Receptor to Translation

  2026-10-07

  A mechanism-led view of Sumatriptan Succinate as a translational research tool, connecting 5-HT1B/1D pharmacology, neurovascular signaling, inflammation hypotheses, and evidence from a pediatric emergency department study.

• Diclofenac and Human Intestinal Organoid Evidence

  2026-10-06

  Diclofenac is a non-selective COX inhibitor with established relevance to inflammation and pain signaling research. This evidence-focused review examines how human iPSC-derived intestinal organoids can clarify cyclooxygenase biology and pharmacokinetic interpretation without overstating what the current literature demonstrates.

• KR-12 Human Antimicrobial Peptide: Evidence Guide

  2026-10-06

  KR-12 is a compact human antimicrobial peptide fragment derived from LL-37. Evidence supports membrane-targeting, anti-biofilm, LPS-neutralizing, and immunoregulatory research relevance, but reported assay conditions and translational boundaries limit direct comparison across studies.

• SB 225002: Evidence, Scope, and CXCR2 Interpretation

  2026-10-05

  A source-grounded overview of what SB 225002 can and cannot show in CXCR2, IL-8, neutrophil chemotaxis, inflammation, and cancer research, with particular attention to a 2026 study linking MRSA extracellular vesicles to CXCR1-centered signaling in oral cancer.

• Phenacetin in Human-Relevant PK Models

  2026-10-05

  Phenacetin can serve as a historically informative, research-only small-molecule comparator for evaluating human-relevant intestinal pharmacokinetic models. This article connects the compound’s uncertain mechanism and nephropathy history with new findings on hiPSC-derived intestinal organoids, while distinguishing platform capability from phenacetin-specific evidence.

7881 records 1/526 page Next 12345 下5页 Last page